New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: Do not let the perfect be the enemy of the good

Clinical Infectious Diseases

Volumn 52, Issue SUPPL. 7, 2011, Pages

  Corey, G Ralph ^a,c   Stryjewski, Martin E ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CEMIC   (Argentina)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ABSCESS; ARTICLE; BACTERIAL SKIN DISEASE; CLINICAL TRIAL (TOPIC); FOOD AND DRUG ADMINISTRATION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; SKIN INFECTION; SKIN STRUCTURE; STATISTICAL ANALYSIS; STUDY DESIGN;

ACUTE DISEASE; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; DRUG APPROVAL; GOVERNMENT REGULATION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955759781     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir162     Document Type: Article

References (58)

1. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006; 12:1715-23. (Pubitemid 44674248)
2. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40:562-73. (Pubitemid 40270226)
3. Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36:627-37.
4. Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91. (Pubitemid 43122317)
5. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009; 301:727-36.
6. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
7. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006; 144:309-17. (Pubitemid 46768185)
8. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(Suppl 5);S368-77. (Pubitemid 351717324)
9. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant Staphylococcus aureus. Lancet 2010; 375:1557-68.
10. Gonzalez BE, Rueda AM, Shelburne SA 3rd, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 2006; 27:1051-6. (Pubitemid 44670980)
11. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71. (Pubitemid 47598444)
12. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006; 42:647-56. (Pubitemid 43271378)
13. Jenkins TC, McCollister BD, Sharma R, et al. Epidemiology of healthcare-associated bloodstream infection caused by USA300 strains of methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Infect Control Hosp Epidemiol 2009; 30:233-41.
14. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staph-ylococcus aureus Working Group. N Engl J Med 1999; 340:493-501.
15. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin Infect Dis 2008; 46:675-7. (Pubitemid 351321549)
16. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 002; 51:565-7.
17. Bae IG, Federspiel JJ, Miro JM, et al. Heterogeneous vancomycin- intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200:1355-66.
18. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350:1670-3. (Pubitemid 28036828)
19. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6. (Pubitemid 44737223)
20. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
21. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304:641-8.
22. Bull JP. The historical development of clinical therapeutic trials. J Chronic Dis 1959; 10:218-48.
23. US Food and Drug Administration, Guidance for Industry: Uncomplicated and Complicated Skin and Skin Structure Infections: Developing Drugs for Treatment. US Food and Drug Administration. July 1998. Available at http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071185. pdf. Accessed 31 August 2010.
24. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81. (Pubitemid 38781657)
25. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus van-comycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008; 46:1683-93. (Pubitemid 351706765)
26. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005; 41(Suppl. 5); S341-53. (Pubitemid 41170381)
27. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46:647-55. (Pubitemid 351321545)
28. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infection. J Antimicrob Chemother 2010; 65(Suppl 4);iv41-51.
29. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 2008; 52:37-44.
30. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51:3612-6. (Pubitemid 47519351)
31. US Food and Drug Administration, Guidance for Industry: Non-Inferiority Clinical Trials. US Food and Drug Administration. March 2010. Available at http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM202140. pdf. Accessed 31 August 2010.
32. Spellberg B, Talbot GH, Boucher HW, et al. Antimicrobial agents for complicated skin and skin-structure infections: justification of non-inferiority margins in the absence of placebo-controlled trials. Clin Infect Dis 2009; 49:383-91.
33. US Food and Drug Administration. Guidance for Industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. US Food and Drug Administration. August 2010. Available at http://www. fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM071185.pdf. Accessed 31 August 2010.
34. Wilson SE, Solomkin JS, Le V, Cammarata SK, Bruss JB. A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am J Surg 2003; 185:369-75. (Pubitemid 36351479)
35. Skinner D, Keefer CS. Significance of bacteremia caused by Staphylo-coccus aureus: a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851-75.
36. Canning J, Barford B, Sullivan D, Wickett R, Visscher M. Use of digital photography and image analysis techniques to quantify erythema in health care workers. Skin Res Technol 2009; 15:24-34.
37. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005; 41:1407-15. (Pubitemid 41579981)
38. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49:2260-6. (Pubitemid 40734452)
39. Hadvary P, Stevens D, Solonets M, Jones M, Sahm D, O'Hare M, et al. Clinical efficacy of Iclaprim in complicated skin and skin structure infection (cSSSI): results of combined ASSIST phase III studies [abstract L-1512]. In: 48th Annual ICAAC/IDSA 46th Annual Meeting. Arlington, VA: Infectious Diseases Society of America, 2008.
40. Figtree M, Konecny P, Jennings Z, Goh C, Krilis SA, Miyakis S. Risk stratification and outcome of cellulitis admitted to hospital. J Infect 2010; 60:431-9.
41. Weitzman ED, Moline ML, Czeisler CA, Zimmerman JC. Chronobi-ology of aging: temperature, sleep-wake rhythms and entrainment. Neurobiol Aging 1982; 3:299-309. (Pubitemid 13086150)
42. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-7. (Pubitemid 38264177)
43. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977; 64:264-6. (Pubitemid 8075132)
44. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15-9. (Pubitemid 15161258)
45. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methi-cillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044-8. (Pubitemid 350057804)
46. Paydar KZ, Hansen SL, Charlebois ED, Harris HW, Young DM. Inappropriate antibiotic use in soft tissue infections. Arch Surg 2006; 141:850-4; discussion 5-6. (Pubitemid 44414426)
47. Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis 2007; 44:777-84. (Pubitemid 46365300)
48. Lee MC, Rios AM, Aten MF, et al. Management and outcome of children with skin and soft tissue abscesses caused by community- acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23:123-7. (Pubitemid 38222783)
49. Snodgrass WR, Anderson T. Prontosil in the treatment of erysipelas: a controlled series of 312 cases. BMJ 1937; 2:101-4.
50. Snodgrass WR, Anderson T. Sulphanilamide in the treatment of erysipelas: a controlled series of 270 cases. BMJ 1937; 2:1156-59.
51. Corwin P, Toop L, McGeoch G, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ 2005; 330:129.
52. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009; 63:368-75.
53. De Anda C, Bien P, Prokocimer P. Oral torezolid Phosphate in the treatment of Severe cSSSI in patients with systemic signs of infection: a phase 2 Dose ranging study [abstract 1921]. In: 20th European Congress of Clinical Microbiology Infectious Diseases. Vienna: European Society of Clinical Microbiology and Infectious Diseases, 2010.
54. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997; 29:377-82.
55. Dall L, Peterson S, Simmons T, Dall A. Rapid resolution of cellulitis in patients managed with combination antibiotic and anti-inflammatory therapy. Cutis 2005; 75:177-80. (Pubitemid 40521814)
56. Fleming TR. Current issues in non-inferiority trials. Stat Med 2008; 27:317-32. (Pubitemid 351227869)
57. Carroll KJ. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way? Pharm Stat 2006; 5:283-93. (Pubitemid 46023757)
58. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-74. (Pubitemid 39037946)